Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration
AL Misko, Y Sasaki, E Tuck, J Milbrandt… - Journal of …, 2012 - Soc Neuroscience
Alterations in mitochondrial dynamics (fission, fusion, and movement) are implicated in
many neurodegenerative diseases, from rare genetic disorders such as Charcot-Marie-Tooth …
many neurodegenerative diseases, from rare genetic disorders such as Charcot-Marie-Tooth …
Delineating the phenotypic spectrum of sulfite oxidase and molybdenum cofactor deficiency
AL Misko, Y Liang, JB Kohl, F Eichler - Neurology: Genetics, 2020 - AAN Enterprises
Objective To define the phenotypic spectrum of isolated sulfite oxidase (ISOD) and molybdenum
cofactor deficiency (MoCD), aiming to promote timely diagnosis and assist in future …
cofactor deficiency (MoCD), aiming to promote timely diagnosis and assist in future …
[HTML][HTML] Progress in elucidating pathophysiology of mucolipidosis IV
Mucolipidosis IV (MLIV) is an autosomal-recessive disease caused by loss-of-function mutations
in the MCOLN1 gene encoding the non-selective cationic lysosomal channel transient …
in the MCOLN1 gene encoding the non-selective cationic lysosomal channel transient …
Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex
A Misko, S Jiang, I Wegorzewska… - Journal of …, 2010 - Soc Neuroscience
Mitofusins (Mfn1 and Mfn2) are outer mitochondrial membrane proteins involved in
regulating mitochondrial dynamics. Mutations in Mfn2 cause Charcot-Marie-Tooth disease (CMT) …
regulating mitochondrial dynamics. Mutations in Mfn2 cause Charcot-Marie-Tooth disease (CMT) …
Early evidence of delayed oligodendrocyte maturation in the mouse model of mucolipidosis type IV
…, SA Slaugenhaupt, A Misko… - Disease models & …, 2020 - journals.biologists.com
Mucolipidosis type IV (MLIV) is a lysosomal disease caused by mutations in the MCOLN1
gene that encodes the endolysosomal transient receptor potential channel mucolipin-1, or …
gene that encodes the endolysosomal transient receptor potential channel mucolipin-1, or …
[HTML][HTML] The role of glutamate oxaloacetate transaminases in sulfite biosynthesis and H2S metabolism
Molybdenum cofactor deficiency and isolated sulfite oxidase deficiency are two rare genetic
disorders that are caused by impairment of the mitochondrial enzyme sulfite oxidase. Sulfite …
disorders that are caused by impairment of the mitochondrial enzyme sulfite oxidase. Sulfite …
MCOLN1 gene therapy corrects neurologic dysfunction in the mouse model of mucolipidosis IV
…, S Slaugenhaupt, A Misko… - Human Molecular …, 2021 - academic.oup.com
Mucolipidosis IV (MLIV) is an orphan disease leading to debilitating psychomotor deficits
and vision loss. It is caused by loss-of-function mutations in the MCOLN1 gene that encodes …
and vision loss. It is caused by loss-of-function mutations in the MCOLN1 gene that encodes …
[HTML][HTML] Sulfite alters the mitochondrial network in molybdenum cofactor deficiency
AT Mellis, J Roeper, AL Misko, J Kohl… - Frontiers in …, 2021 - frontiersin.org
Molybdenum cofactor deficiency (MoCD) is an autosomal recessive disorder belonging to the
large family of inborn errors in metabolism. Patients typically present with encephalopathy …
large family of inborn errors in metabolism. Patients typically present with encephalopathy …
White matter abnormalities and iron deposition in prenatal mucolipidosis IV-fetal imaging and pathology
…, Y Fisher, R Schiffmann, Y Grishchuk, AL Misko… - Metabolic Brain …, 2021 - Springer
Mucolipidosis type IV (MLIV; OMIM 252,650) is an autosomal recessive lysosomal disorder
caused by mutations in MCOLN1. MLIV causes psychomotor impairment and progressive …
caused by mutations in MCOLN1. MLIV causes psychomotor impairment and progressive …
Cross-sectional Observations on the Natural History of Mucolipidosis Type IV
AL Misko, LB Wood, M DeBono, R Oberman… - Neurology …, 2022 - AAN Enterprises
Background and Objectives Mucolipidosis type IV (MLIV) is an ultra-rare lysosomal disorder
initially described as a static neurodevelopmental condition. However, patient caregivers …
initially described as a static neurodevelopmental condition. However, patient caregivers …